Interest in Type 2 Diabetes Research Topics in PAR-13-055 "Dissemination and Implementation Research in Health (R01)" to support the Global Alliance for Chronic Diseases (GACD) Initiative

Notice Number: NOT-TW-14-005

Key Dates
Release Date: December 5, 2013

Related Announcements
PAR-13-055

Issued by
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Office of Behavioral and Social Sciences Research (OBSSR)

Purpose

The National Institutes of Health is a participant in the Global Alliance for Chronic Diseases (GACD) (www.gacd.org), a collection of publicly funded research agencies that supports innovative research collaborations to address the prevention and treatment of chronic diseases in vulnerable populations.
GACD member organizations are currently soliciting applications on type 2 diabetes with a focus on improving the science around implementation of existing interventions (GACD Calls for Proposals).

The above listed components of the NIH invite interested researchers to submit applications in this area through the existing trans-NIH Initiative on Dissemination and Implementation Science (PAR-13-055). Applicants need to identify the GACD initiative in their abstracts and cover letters. Of note, only applications received for the February 2014 due date will be considered responsive to this notice.

The particular interests of the ICs in this Notice are as follows:

NHLBI is interested in R01 applications from US domestic institutions, in partnership with LMICs institutions, with proposed work in low and middle income countries that address the following:

  • Studies employing multidisciplinary teams testing implementation and dissemination strategies of delivering efficacious weight loss interventions among diabetics or those at high risk for the development of diabetes.  Targets could include providers, health care systems, patients, community workers or other community resources.
  • Programs that employ  community health workers to 1) deliver evidence-based lifestyle, self-management, and pharmacological treatments for the reduction of cardiovascular disease risk among diabetic patients; 2) deliver culturally appropriate information on early detection and treatment interventions for diabetes in underserved communities; and/or 3) promote the prevention of obesity and chronic disease in underserved communities with diabetes.
  • Investigations testing the effectiveness of community health workers in assessing the long term sustainability of prevention and treatment approaches (e.g., behavioral and/or pharmacological) of cardiovascular risk factors in diabetics.
  • Investigations to improve patient and provider adherence to treatments among diabetic patients with or at risk for co-morbid cardiovascular diseases.
  • Investigations testing delivery and maintenance strategies of effective pharmacological, lifestyle, and self-management treatments and behaviors to prevent the subsequent development or progression of cardiovascular diseases.
  • Investigations of the effectiveness of implementation strategies to reduce health disparities among underserved populations at risk for co-morbid cardiovascular conditions.
  • Programs testing implementation approaches to symptom management to decrease the burden of disease in diabetic patients with co-morbid cardiovascular conditions.

NIDDK will entertain R01 research applications under the GACD initiative that are focused on type 2 diabetes prevention and control in American Indian populations, as well as racial and ethnic minorities and other vulnerable populations in the United States.

OBSSR is interested in co-funding scientifically meritorious applications that align with the interests of the participating Institutes and Centers, and are also relevant to behavioral and social science research and OBSSR’s mission which can be found at: http://obssr.od.nih.gov/about_obssr/mission/mission.aspx.

Inquiries

Cristina Rabad n-Diehl, PhD, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-3620
Email: [email protected]